Our study found a somewhat different pattern of sensitivity to drugs in PDX coming from chemotherapy-naïve TNBC patients with and without mutations in genes involved in DNA homologous recombination repair (BCRA1 and PALB2) and hereditary breast cancer. The gene discussed is PALB2; the disease is breast carcinoma.